JPRN-UMIN000031295尚未招募未知
A double-blind, placebo-controlled study with A-2 on symptoms of vaginal atrophy in postmenopausal women - Effect of A-2 on symptoms of vaginal atrophy in postmenopausal women
Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital0 个研究点目标入组 50 人开始时间: 2021年5月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45years-old 至 65years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Diversity from normal ranges of vital signs, and in clinical laboratory tests 2) Current or past reproductive-related cancer and so forth 3) Serious illumes 4) Allergies to soy or lactose 5) Individuals who are diagnosed as inappropriate for the trial by the principal Investigator
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to see if there are differences in flu symptoms when people receive a single infusion of VIS410, the study medicine, compared with those who receive placebo and to find out if VIS410 is safe and well toleratedInfluenza A infectionMedDRA version: 19.0Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862EUCTR2015-004546-26-LVVisterra, Inc.150
进行中（未招募）
1 期
Clinical trial to see if there are differences in flu symptoms when people receive a single infusion of VIS410, the study medicine, compared with those who receive placebo and to find out if VIS410 is safe and well toleratedInfluenza A infectionMedDRA version: 19.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862EUCTR2015-004546-26-BGVisterra, Inc.150
进行中（未招募）
1 期
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEUCTR2010-020127-52-DKAstraZeneca AB90
进行中（未招募）
不适用
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaChronic obstructive pulmonary disease and Sputum EosinophiliaMedDRA version: 13.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-020127-52-DEAstraZeneca AB90
进行中（未招募）
1 期
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEUCTR2010-020127-52-GBAstraZeneca AB101